Educational guide
PepLib Biotech Enters Global Peptide Drug Discovery And ...
BioPharma PepLib Biotech Enters Global Peptide Drug Discovery And Licensing Collaboration With Eli Lilly PepLib Biotech Enters Global Peptide Drug Discovery And Licensing Collaboration With Eli Lilly 06 February 2026 | Friday | News The agreement enables Zonse
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
- BioPharma
- PepLib Biotech Enters Global Peptide Drug Discovery And Licensing Collaboration With Eli Lilly
PepLib Biotech Enters Global Peptide Drug Discovery And Licensing Collaboration With Eli Lilly
06 February 2026 | Friday | News
The agreement enables Zonsen PepLib Biotech Inc. and Eli Lilly and Company to jointly advance novel peptide based therapeutics, combining PepLib’s proprietary discovery platforms with Lilly’s IND development clinical and commercial capabilities to accelerate innovation across multiple disease areas.
Zonsen PepLib Biotech Inc. (“PepLib”) announced that it has entered a global research and development (R&D) collaboration and license agreement with Eli Lilly and Company ("Lilly"). Under the agreement, both parties will jointly advance the development of novel peptide-based drug candidates leveraging PepLib’s robust and diverse proprietary peptide libraries and discovery technology platforms.
PepLib will be responsible for screening and identifying optimal peptide active molecules for the collaborative projects based on its in-house platform, while Lilly will lead subsequent Investigational New Drug (IND) enabling studies, clinical development, and commercialization.
Under the terms of the agreement, PepLib will receive upfront and near-term payments. Additionally, PepLib is eligible to receive subsequent development, regulatory, and sales milestone payments, as well as tiered royalties on future global net sales.
“This collaboration further validates PepLib’s innovative and differentiated peptide R&D platforms. As a global leader across multiple disease areas, Lilly is our valued partner. We look forward to the close collaboration to develop novel therapeutic strategies for diseases and deliver benefits to patients worldwide,” said Lei Chen, Chairman and Co-founder of PepLib.
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
Editor Picks
Stay Connected
Sign up to our free newsletter and get the latest news sent direct to your inbox